Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- VCEL
- Price
- 39.14
- Stock movement up
- +1.42 (3.76%)
- Company name
- Vericel Corp Ord
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.98B
- Ent value
- 2.01B
- Price/Sales
- 7.65
- Price/Book
- 6.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 151.31
- Forward P/E
- 67.48
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -34.28%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VCEL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 151.31 |
| Price to OCF | 33.47 |
| Price to FCF | 138.45 |
| Price to EBITDA | 83.83 |
| EV to EBITDA | 85.14 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.65 |
| Price to Book | 6.15 |
| EV to Sales | 7.77 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.57M |
| EPS (TTM) | 0.25 |
| FCF per share (TTM) | 0.28 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 258.72M |
| Gross profit (TTM) | 190.97M |
| Operating income (TTM) | 7.11M |
| Net income (TTM) | 13.08M |
| EPS (TTM) | 0.25 |
| EPS (1y forward) | 0.58 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 73.81% |
| Operating margin (TTM) | 2.75% |
| Profit margin (TTM) | 5.06% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 100.40M |
| Net receivables | 60.43M |
| Total current assets | 221.97M |
| Goodwill | 0.00 |
| Intangible assets | 5.78M |
| Property, plant and equipment | 204.18M |
| Total assets | 453.27M |
| Accounts payable | 15.34M |
| Short/Current long term debt | 98.01M |
| Total current liabilities | 45.58M |
| Total liabilities | 131.42M |
| Shareholder's equity | 321.86M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 59.14M |
| Capital expenditures (TTM) | 44.84M |
| Free cash flow (TTM) | 14.30M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 4.06% |
| Return on Assets | 2.89% |
| Return on Invested Capital | 3.74% |
| Cash Return on Invested Capital | 4.09% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 37.74 |
| Daily high | 39.46 |
| Daily low | 37.72 |
| Daily Volume | 494K |
| All-time high | 1410.00 |
| 1y analyst estimate | 55.00 |
| Beta | 1.18 |
| EPS (TTM) | 0.25 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| VCEL | S&P500 | |
| Current price drop from All-time high | -97.22% | -0.89% |
| Highest price drop | -97.88% | -19.00% |
| Date of highest drop | 25 Sep 2025 | 8 Apr 2025 |
| Avg drop from high | -96.92% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.98B
Marketcap category
Small-cap
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Employees
357
Website
Investor relations
-
SEC filings
CEO
Dominick C. Colangelo
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page